Radicava (Edaravone) Patent Expiration, LOE Window & CMS Spending

Radicava (Edaravone) by Mitsubishi Tana: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $5.4M 2024 CMS Part D & Medicaid spend, and $1,272 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMitsubishi Tana
FDA Application & PathwayN209176 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$5.4M
2024 Medicare Part D Spend$4.9M
2024 Medicaid Spend$491K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,272 intro WAC)